Sero-prevalence of hepatitis B virus markers and associated factors among children in Hawassa City, southern Ethiopia.
Biomarkers
/ blood
Child
Child, Preschool
Cross-Sectional Studies
Ethiopia
/ epidemiology
Female
Hepatitis B
/ blood
Hepatitis B Antibodies
/ blood
Hepatitis B Surface Antigens
/ blood
Hepatitis B Vaccines
/ administration & dosage
Hepatitis B virus
/ immunology
Humans
Infectious Disease Transmission, Vertical
/ prevention & control
Male
Pregnancy
Pregnancy Complications, Infectious
/ blood
Prenatal Care
/ methods
Prevalence
Risk Factors
Surveys and Questionnaires
Vaccination
/ methods
Hawassa
Hepatitis B virus
Sero-prevalence
Southern Ethiopia
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
22 Jul 2020
22 Jul 2020
Historique:
received:
09
12
2019
accepted:
03
07
2020
entrez:
24
7
2020
pubmed:
24
7
2020
medline:
29
8
2020
Statut:
epublish
Résumé
Hepatitis B virus (HBV) infection is one of the major public health problems worldwide. Limited information exists about the epidemiology of HBV infection in Ethiopia. This study aimed to assess sero-prevalence of HBV markers and associated factors in children living in Hawassa City, southern Ethiopia. A community-based cross-sectional study was conducted among 471 children in Hawassa City, southern Ethiopia from May to September, 2018. A total of 471 children were included in the study using a multistage sampling technique. Data on demographic and risk factors were gathered using structured questionnaires. Blood samples were collected and sera were screened for hepatitis B surface antigen (HBsAg), antibody to core antigen (anti-HBc), and antibody against surface antigen (anti-HBs) using enzyme-linked immunosorbent assay. The sero-prevalence of HBsAg, anti-HBc, and anti-HBs markers among children were 4.4, 19.5 and 20.0%, respectively. Children at higher risk of having HBsAg marker were those who had a history of injectable medications (AOR 5.02, 95% CI: 1.14, 22.07), a family history of liver disease (AOR 6.37, 95% CI: 1.32, 30.74), a HBsAg seropositive mothers, (AOR 11.19, (95% CI: 3.15, 39.67), and had no vaccination history for HBV (AOR, 6.37, 95% CI: 1.32, 30.74). Children from families with low monthly income, who were home delivered, unvaccinated for HBV or with HBsAg seropositive mother had increased risk of having anti-HBc. The study findings showed an intermediate endemicity of HBV infection in the study setting. The observed rate of residual HBV infection with low rate of immunized children after HBV vaccination was high. Hence, introducing birth dose vaccine, safe injection practice and improving immunization coverage during pregnancy as part of the antenatal care package should be considered. Furthermore, governmental and non-governmental organizations should give attention on timely measures for the prevention of ongoing vertical transmission from mother to child as well as early horizontal transmission of HBV in Hawassa City, Ethiopia.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis B virus (HBV) infection is one of the major public health problems worldwide. Limited information exists about the epidemiology of HBV infection in Ethiopia. This study aimed to assess sero-prevalence of HBV markers and associated factors in children living in Hawassa City, southern Ethiopia.
METHODS
METHODS
A community-based cross-sectional study was conducted among 471 children in Hawassa City, southern Ethiopia from May to September, 2018. A total of 471 children were included in the study using a multistage sampling technique. Data on demographic and risk factors were gathered using structured questionnaires. Blood samples were collected and sera were screened for hepatitis B surface antigen (HBsAg), antibody to core antigen (anti-HBc), and antibody against surface antigen (anti-HBs) using enzyme-linked immunosorbent assay.
RESULTS
RESULTS
The sero-prevalence of HBsAg, anti-HBc, and anti-HBs markers among children were 4.4, 19.5 and 20.0%, respectively. Children at higher risk of having HBsAg marker were those who had a history of injectable medications (AOR 5.02, 95% CI: 1.14, 22.07), a family history of liver disease (AOR 6.37, 95% CI: 1.32, 30.74), a HBsAg seropositive mothers, (AOR 11.19, (95% CI: 3.15, 39.67), and had no vaccination history for HBV (AOR, 6.37, 95% CI: 1.32, 30.74). Children from families with low monthly income, who were home delivered, unvaccinated for HBV or with HBsAg seropositive mother had increased risk of having anti-HBc.
CONCLUSIONS
CONCLUSIONS
The study findings showed an intermediate endemicity of HBV infection in the study setting. The observed rate of residual HBV infection with low rate of immunized children after HBV vaccination was high. Hence, introducing birth dose vaccine, safe injection practice and improving immunization coverage during pregnancy as part of the antenatal care package should be considered. Furthermore, governmental and non-governmental organizations should give attention on timely measures for the prevention of ongoing vertical transmission from mother to child as well as early horizontal transmission of HBV in Hawassa City, Ethiopia.
Identifiants
pubmed: 32698884
doi: 10.1186/s12879-020-05229-7
pii: 10.1186/s12879-020-05229-7
pmc: PMC7374845
doi:
Substances chimiques
Biomarkers
0
Hepatitis B Antibodies
0
Hepatitis B Surface Antigens
0
Hepatitis B Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
528Références
World J Gastroenterol. 2014 May 14;20(18):5427-34
pubmed: 24833873
J Infect Dis. 2003 Jan 1;187(1):134-8
pubmed: 12508157
Am Fam Physician. 2010 Nov 15;82(10):1225-9
pubmed: 21121533
J Viral Hepat. 2014 Jun;21(6):381-96
pubmed: 24827901
J Viral Hepat. 2004 Mar;11(2):97-107
pubmed: 14996343
Int J Infect Dis. 2015 Jul;36:21-6
pubmed: 25957815
Vaccine. 2008 Nov 18;26(49):6266-73
pubmed: 18848855
J Pak Med Assoc. 2007 Aug;57(8):391-5
pubmed: 17902521
J Pediatr. 1979 Oct;95(4):647-50
pubmed: 556543
J Hepatol. 1994 Aug;21(2):250-4
pubmed: 7989718
Korean J Intern Med. 2013 Jul;28(4):413-9
pubmed: 23864799
Epidemiol Infect. 2003 Aug;131(1):757-70
pubmed: 12948377
BMC Res Notes. 2014 Apr 15;7:239
pubmed: 24731794
Int J Infect Dis. 2010 Nov;14(11):e928-40
pubmed: 20678951
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
J Hepatol. 2015 Feb;62(2):469-76
pubmed: 25457207
J Pak Med Assoc. 2014 Apr;64(4):403-8
pubmed: 24864633
Gut Liver. 2012 Apr;6(2):235-40
pubmed: 22570754
J Pregnancy. 2018 Aug 5;2018:8435910
pubmed: 30174956
World J Hepatol. 2015 Oct 8;7(22):2418-26
pubmed: 26464758
J Epidemiol Community Health. 2010 Oct;64(10):890-4
pubmed: 19822551
Am J Trop Med Hyg. 2015 Mar;92(3):501-6
pubmed: 25582692
Am J Trop Med Hyg. 2007 Dec;77(6):1079-86
pubmed: 18165526
BMC Infect Dis. 2014 Jan 07;14:7
pubmed: 24397793
Afr Health Sci. 2009 Jun;9(2):98-108
pubmed: 19652743
Bull World Health Organ. 2014 Nov 1;92(11):782-9
pubmed: 25378739